Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantifying the effect of experimental perturbations at single-cell resolution.
Burkhardt DB, Stanley JS 3rd, Tong A, Perdigoto AL, Gigante SA, Herold KC, Wolf G, Giraldez AJ, van Dijk D, Krishnaswamy S. Burkhardt DB, et al. Among authors: perdigoto al. Nat Biotechnol. 2021 May;39(5):619-629. doi: 10.1038/s41587-020-00803-5. Epub 2021 Feb 8. Nat Biotechnol. 2021. PMID: 33558698 Free PMC article.
Inducing and Administering Tregs to Treat Human Disease.
Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC. Perdigoto AL, et al. Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654. eCollection 2015. Front Immunol. 2016. PMID: 26834735 Free PMC article. Review.
Have we pushed the needle for treatment of Type 1 diabetes?
Naushad N, Perdigoto AL, Rui J, Herold KC. Naushad N, et al. Among authors: perdigoto al. Curr Opin Immunol. 2017 Dec;49:44-50. doi: 10.1016/j.coi.2017.09.004. Epub 2017 Oct 6. Curr Opin Immunol. 2017. PMID: 28992525 Free PMC article. Review.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Stamatouli AM, et al. Among authors: perdigoto al. Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24. Diabetes. 2018. PMID: 29937434 Free PMC article. Review.
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network. Perdigoto AL, et al. Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19. Diabetologia. 2019. PMID: 30569273 Free PMC article.
β cell responses to inflammation.
Usmani-Brown S, Perdigoto AL, Lavoie N, Clark P, Korah M, Rui J, Betancur G, Herold KC. Usmani-Brown S, et al. Among authors: perdigoto al. Mol Metab. 2019 Sep;27S(Suppl):S104-S113. doi: 10.1016/j.molmet.2019.06.013. Mol Metab. 2019. PMID: 31500821 Free PMC article. Review.
31 results